Allarity Therapeutics, Inc.
ALLR
NASDAQ·Healthcare·Biotechnology·Mkt cap $22.6M
$1.42
▼ -0.70%
P/E
-3.74
Mkt Cap
$22.6M
52-Wk Range
$0.77–$2.06
52-Week Range
$0.77 - $2.06
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 27.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-11.8% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ALLR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 12, 2026
AUG 14, 2026
Reported EPS of -$0.21 vs -$0.25 consensus (+16.0% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+16.0%
Revenue trend · last 2Q
—
—
Q1 26
Q2 26
$25.0K
$0
Margins · last 2Q
Profit
—
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Ascendiant Capital · Apr 10, 2026
vs Industry
How ALLR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.